| Literature DB >> 15824361 |
D M Wingerchuk1, E E Benarroch, P C O'Brien, B M Keegan, C F Lucchinetti, J H Noseworthy, B G Weinshenker, M Rodriguez.
Abstract
Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15824361 DOI： 10.1212/01.WNL.0000156803.23698.9A
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910